GLIS3 Gene Expression and Clinical Data for Stomach Adenocarcinoma

GLIS3 expression data from 133 paired stomach adenocarcinoma tissues, showing a median H-score of 112 in tumors versus 39 in normal tissue. The dataset includes transcriptomic analyses from The Cancer Genome Atlas, Genotype-Tissue Expression, and Gene Expression Omnibus, compiled by author Qi Xiao and last updated in May 2026. It supports investigation into the GLIS3–TGFBR3–Hedgehog signaling axis linked to epithelial–mesenchymal transition and cancer stem–like traits.

Use Cases

• Assess GLIS3 as a prognostic biomarker for patient survival based on its association with adverse clinicopathological features.
• Investigate the relationship between GLIS3 expression and epithelial–mesenchymal transition marker switching described in the study.
• Model the GLIS3–TGFBR3–Hedgehog signaling cascade using the gene expression and mechanistic data referenced.
• Validate findings from gain- and loss-of-function studies in AGS and HGC-27 cell lines using the provided clinical cohort data.

Strengths

• Includes immunohistochemistry data from 133 paired clinical tissue samples.
• Integrates transcriptomic data from three major public repositories: TCGA, GTEx, and GEO.
• Clinical correlations are supported by multivariable Cox models, reporting a hazard ratio of 1.45 for overall survival.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The primary data file is a 16.4 KB DOCX document, suggesting a limited scope of raw data.

Provenance

Source

The Cancer Genome Atlas, Genotype-Tissue Expression, Gene Expression Omnibus, and a clinical cohort of 133 paired tissues.

Collection Method

Transcriptomic analysis, immunohistochemistry, and in vitro/vivo functional studies.

Freshness

Last updated 2026-05-21 04:19:29; freshness should be verified.